Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efsubaglutide alfa 3 mg every 2 weeks versus 1 mg weekly in type 2 diabetes mellitus
CTR20244074Phase 2Completed
- Sponsor
- Yinnuo Pharmaceutical
- Start
- Nov 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of efsubaglutide alfa in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Yinnuo Pharmaceutical. Primary endpoint: Change from baseline in HbA1c. Started Nov 2024; status: completed.
02
Drugs
efsubaglutide alfa
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20244074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244074.